» Articles » PMID: 19646987

MTS Dye Based Colorimetric CTLL-2 Cell Proliferation Assay for Product Release and Stability Monitoring of Interleukin-15: Assay Qualification, Standardization and Statistical Analysis

Overview
Publisher Elsevier
Date 2009 Aug 4
PMID 19646987
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

A colorimetric cell proliferation assay using soluble tetrazolium salt [(CellTiter 96(R) Aqueous One Solution) cell proliferation reagent, containing the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and an electron coupling reagent phenazine ethosulfate], was optimized and qualified for quantitative determination of IL-15 dependent CTLL-2 cell proliferation activity. An in-house recombinant Human (rHu)IL-15 reference lot was standardized (IU/mg) against an international reference standard. Specificity of the assay for IL-15 was documented by illustrating the ability of neutralizing anti-IL-15 antibodies to block the product specific CTLL-2 cell proliferation and the lack of blocking effect with anti-IL-2 antibodies. Under the defined assay conditions, the linear dose-response concentration range was between 0.04 and 0.17ng/ml of the rHuIL-15 produced in-house and 0.5-3.0IU/ml for the international standard. Statistical analysis of the data was performed with the use of scripts written in the R Statistical Language and Environment utilizing a four-parameter logistic regression fit analysis procedure. The overall variation in the ED(50) values for the in-house reference standard from 55 independent estimates performed over the period of 1year was 12.3% of the average. Excellent intra-plate and within-day/inter-plate consistency was observed for all four parameter estimates in the model. Different preparations of rHuIL-15 showed excellent intra-plate consistency in the parameter estimates corresponding to the lower and upper asymptotes as well as to the 'slope' factor at the mid-point. The ED(50) values showed statistically significant differences for different lots and for control versus stressed samples. Three R-scripts improve data analysis capabilities allowing one to describe assay variations, to draw inferences between data sets from formal statistical tests, and to set up improved assay acceptance criteria based on comparability and consistency in the four parameters of the model. The assay is precise, accurate and robust and can be fully validated. Applications of the assay were established including process development support, release of the rHuIL-15 product for pre-clinical and clinical studies, and for monitoring storage stability.

Citing Articles

A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy.

Shrestha N, Dee M, Chaturvedi P, Leclerc G, Mathyer M, Dufour C Cancer Immunol Immunother. 2024; 73(9):179.

PMID: 38960949 PMC: 11222348. DOI: 10.1007/s00262-024-03765-8.


Refined control of CRISPR-Cas9 gene editing in : the creation of recombinant strains for therapeutic applications.

Kubiak A, Claessen L, Zhang Y, Khazaie K, Bailey T Front Immunol. 2023; 14:1241632.

PMID: 37869009 PMC: 10585264. DOI: 10.3389/fimmu.2023.1241632.


A peptoid interleukin-15 receptor antagonist suppresses inflammation and arthritis in mice.

Cho K, Shukla S, Kannan M, Zhang H, Amina S, Zhou S Clin Transl Immunology. 2022; 11(11):e1432.

PMID: 36439637 PMC: 9686008. DOI: 10.1002/cti2.1432.


Addressing artifacts of colorimetric anticancer assays for plant-based drug development.

Batool S, Javaid S, Javed H, Asim L, Shahid I, Khan M Med Oncol. 2022; 39(12):198.

PMID: 36071299 DOI: 10.1007/s12032-022-01791-z.


Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles.

Asavarut P, Waramit S, Suwan K, Marais G, Chongchai A, Benjathummarak S EMBO Mol Med. 2022; 14(8):e15418.

PMID: 35758207 PMC: 9358398. DOI: 10.15252/emmm.202115418.


References
1.
Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D . Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271(12):907-13. View

2.
Grabstein K, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V . Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994; 264(5161):965-8. DOI: 10.1126/science.8178155. View

3.
Mattei F, Schiavoni G, Belardelli F, Tough D . IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol. 2001; 167(3):1179-87. DOI: 10.4049/jimmunol.167.3.1179. View

4.
Fehniger T, Caligiuri M . Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol. 2002; 20(3-4):503-34. DOI: 10.3109/08830180109054417. View

5.
Buttke T, McCubrey J, Owen T . Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods. 1993; 157(1-2):233-40. DOI: 10.1016/0022-1759(93)90092-l. View